Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Slingshot Biosciences has raised $15.0M in total funding. The most recent round was Series A. The last funding was announced in April 2024.
Slingshot Biosciences's investors include ARCH Venture Partners, Anterra Capital, Northpond Ventures, Tao Capital Partners, ImpactAssets.
Slingshot Biosciences is headquartered in Emeryville, United States.
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Slingshot Biosciences is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Slingshot Biosciences — Funding & Investors." VCBacked, April 26, 2024, https://www.vcbacked.co/company/slingshot-biosciences. Accessed July 20, 2026.
VCBacked. (2024). Slingshot Biosciences — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/slingshot-biosciences
{{cite web |title=Slingshot Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/slingshot-biosciences |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated